Lead Sponsor

Bristol-Myers Squibb

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•For Cohort 1 and 2: (Recruitment ended by 02/20/2020)
•Advanced melanoma (Stage III/Stage IV)
•Histologically confirmed diagnosis
•Treatment decision for nivolumab monotherapy or nivolumab/ipilimumab combination therapy has already been taken
•For Cohort 3: (Recruitment ended by 08/31/2020)
•Primary diagnosis of advanced melanoma after complete surgical tumor resection and no evidence of disease
•Treatment decision for adjuvant nivolumab therapy has already been taken

•For Cohort 1 and 2: (Recruitment ended by 02/20/2020)
•Current primary diagnosis of a cancer other than advanced melanoma, that requires systemic or other treatment or has not been treated curatively (as per discretion of the investigator)
•Previous treatment with nivolumab, for nivolumab monotherapy cohort only
•Current active participation in an interventional clinical trial
•For Cohort 3: (Recruitment ended by 08/31/2020)
•Current diagnosis of persisting advanced melanoma or a cancer other than advanced melanoma that requires systemic or other treatment or has not been treated curatively (as per discretion of the investigator)
•Current active participation in an interventional clinical trial

Related studies

NCT06961357 · Melanoma

NCT07379138 · Melanoma

NCT06529822 · Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, and more

NCT05076760 · Solid Tumor, Advanced Cancer, and more

NCT04855435 · Advanced Solid Tumor, Uveal Melanoma, Metastatic, and more

Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy